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HARM REDUCTION IN FIGHT AGAINST HIV
Harm reduction interventions should encompass
people who inject image and performance enhancing
drugs
Jim McVeigh director 1, Andreas Kimergård principal research fellow 2, Geoff Bates public health
researcher 1, Vivian D Hope principal scientist 3, Fortune Ncube consultant epidemiologist 3
1Centre for Public Health, Liverpool John Moores University, Liverpool L3 2ET, UK; 2Addictions Department, King’s College London, London, UK;
3National Infection Service, Public Health England, London, UK
Wewelcome the news item on the role of harm reduction in the
“fight” against HIV,1 and we broadly agree with the findings of
the report The Case for a Harm Reduction Decade: Progress,
Potential and Paradigm Shifts.2 Clearly harm reduction for
people who inject drugs is having a positive impact on HIV in
many places around the world.
In addition to answering the needs of established drug injecting
populations, we must also get ahead of the curve in relation to
emerging patterns of injecting drug use to reduce the number
of new cases of HIV. The injection of image and performance
enhancing drugs (IPEDs)—such as anabolic steroids, growth
hormones, melanotan II, and a range of other enhancement
drugs—has been largely overlooked in relation to the risk of
transmitting blood borne viruses.
A recent review of 187 studies on anabolic steroid use indicated
a global lifetime prevalence of 3.3%,3 and IPED users are a
growing client group in many countries with longstanding
provision of needle and syringe programmes.4 5 Furthermore,
in the UK there is evidence of HIV within this group, with an
HIV prevalence of 1.5% inmenwho inject IPEDs—comparable
to that in those who inject opioids or stimulants.6 Finally, there
is evidence that people using IPEDs are very sexually active,
with low rates of condom use, suggesting a serious risk of HIV
transmission through their sexual networks.6
The use of IPEDs, and in particular the injection of anabolic
steroids by men, must be viewed as a serious public health
concern requiring the attention of policy makers. Addressing
the needs of emerging and often hidden populations of people
who inject drugs should be part of the focus on harm reduction
interventions.
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